Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$16.85
-0.93 (-5.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $115.2M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
33.0x
↑EV/EBITDA
19.4x
↑ROE
11.3%
↑Gross Margin
82.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.4%
FCF CAGR
+20.9%
FCF margin
18.1%
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $636.3M · net income $92.6M · FCF $115.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $636.3M | $636.3M | $651.9M | $667.0M | $856.7M |
| Net Income | $92.6M | $92.6M | $45.9M | $15.4M | $44.1M |
| EBITDA | $133.8M | $133.8M | $82.5M | $48.9M | $80.2M |
| EPS | 0.50 | 0.50 | 0.25 | 0.08 | 0.23 |
| Gross Margin | 82.1% | 82.1% | 68.5% | 51.2% | 43.9% |
| Operating Margin | 15.5% | 15.5% | 8.9% | 4.7% | 6.6% |
| Net Margin | 14.6% | 14.6% | 7.0% | 2.3% | 5.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.07 |
| Current Ratio | 2.78 | 2.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $115.2M | $115.2M | $99.3M | $163.7M | $65.3M |
| Returns | |||||
| ROE | 11.3% | 11.3% | 6.2% | 2.1% | 5.9% |
| Valuation | |||||
| P/E | 33.04 | 33.04 | 40.08 | 148.50 | 45.04 |
| EV/EBITDA | 19.38 | 19.38 | 17.41 | 39.05 | 21.40 |
| P/B | 3.82 | 3.82 | 2.49 | 3.07 | 2.67 |
| Growth & Yield | |||||
| Revenue Growth | -2.4% | -2.4% | -2.3% | -22.1% | — |
| EPS Growth | 100.0% | 100.0% | 212.5% | -65.2% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
44.1%
EPS terminal req.
$1.50
Spread vs growth
55.9%
5Y implied EPS CAGR
29.3%
EPS terminal req.
$1.81
Spread vs growth
70.7%
10Y implied EPS CAGR
19.3%
EPS terminal req.
$2.91
Spread vs growth
80.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+45.1%
Start / end P/E
46.6x → 33.7x
EPS bridge
0.25 → 0.50
Residual
-27.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.